The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Immune dysregulation as a driver of idiopathic pulmonary fibrosis
Open accessAbstract
Idiopathic pulmonary fibrosis (IPF) affects hundreds of thousands of people worldwide, reducing their quality of life and leading to death from respiratory failure within years of diagnosis. Treatment options remain limited, with only two FDA-approved drugs available in the United States, neither of which reverse the lung damage caused by the disease or prolong the life of individuals with IPF. The only cure for IPF is lung transplantation. In this review, we discuss recent major advances in our understanding of the role of the immune system in IPF that have revealed immune dysregulation as a critical driver of disease pathophysiology. We also highlight ways in which an improved understanding of the immune system's role in IPF may enable the development of targeted immunomodulatory therapies that successfully halt or potentially even reverse lung fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Macrophage activation and polarization: nomenclature and experimental guidelines
Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337
Alternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Macrophages in Tissue Repair, Regeneration, and Fibrosis
Wynn, T. A., & Vannella, K. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.015 · Cited by 4,481
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
M-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287
Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., et al. (1992) · Nature · doi:10.1038/359693a0 · Cited by 2,985
Murray, P. J. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034339 · Cited by 2,981
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Hydrocortisone Therapy for Patients with Septic Shock
Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., Weiss, Y. G., Benbenishty, J., Kalenka, A., Forst, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa071366 · Cited by 2,132
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Zhu, Z., Homer, R. J., Wang, Z., Chen, Q., Geba, G. P., Wang, J., Zhang, Y., & Elias, J. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5909 · Cited by 1,719
Prednisone, Azathioprine, and N -Acetylcysteine for Pulmonary Fibrosis
The Idiopathic Pulmonary Fibrosis Clinical Research Network (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113354 · Cited by 1,621
Cellular senescence mediates fibrotic pulmonary disease
Schafer, M. J., White, T. A., Iijima, K., Haak, A. J., Ligresti, G., Atkinson, E. J., Oberg, A. L., Birch, J., Salmonowicz, H., Zhu, Y., et al. (2017) · Nature Communications · doi:10.1038/ncomms14532 · Cited by 1,613 · cited 1×
“This may be exacerbated by cellular senescence in epithelial cells and fibroblasts, which results in increased production of profibrotic mediators (15).”
BackgroundAcute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., Lee, J. S., Maher, T. M., Wells, A. U., Antoniou, K. M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0801ci · Cited by 1,444
Alveolar macrophages: plasticity in a tissue-specific context
Hussell, T., & Bell, T. J. (2014) · Nature Reviews Immunology · doi:10.1038/nri3600 · Cited by 1,377
Telomerase Mutations in Families with Idiopathic Pulmonary Fibrosis
Armanios, M. Y., Chen, J. J.-L., Cogan, J. D., Alder, J. K., Ingersoll, R. G., Markin, C., Lawson, W. E., Xie, M., Vulto, I., Phillips, J. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066157 · Cited by 1,357 · cited 1×
“This suggestion stems from the finding that families with short telomere syndromes are predisposed to developing pulmonary fibrosis (18).”
BackgroundGuilliams, M., De Kleer, I., Henri, S., Post, S., Vanhoutte, L., De Prijck, S., Deswarte, K., Malissen, B., Hammad, H., & Lambrecht, B. N. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20131199 · Cited by 1,276
Reyfman, P. A., Walter, J. M., Joshi, N., Anekalla, K. R., McQuattie-Pimentel, A. C., Chiu, S., Fernandez, R., Akbarpour, M., Chen, C.-I., Ren, Z., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201712-2410oc · Cited by 1,203
Biernacka, A., Dobaczewski, M., & Frangogiannis, N. G. (2011) · Growth Factors · doi:10.3109/08977194.2011.595714 · Cited by 1,161
Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span
Misharin, A. V., Morales-Nebreda, L., Reyfman, P. A., Cuda, C. M., Walter, J. M., McQuattie-Pimentel, A. C., Chen, C.-I., Anekalla, K. R., Joshi, N., Williams, K. J. N., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162152 · Cited by 1,133
Sime, P. J., Xing, Z., Graham, F. L., Csaky, K. G., & Gauldie, J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119590 · Cited by 1,050
Predicting Survival in Idiopathic Pulmonary Fibrosis
KING, T. E., TOOZE, J. A., SCHWARZ, M. I., BROWN, K. R., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.7.2003140 · Cited by 853
Bleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent
Wilson, M. S., Madala, S. K., Ramalingam, T. R., Gochuico, B. R., Rosas, I. O., Cheever, A. W., & Wynn, T. A. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092121 · Cited by 730
Raghu, G., Chen, S.-Y., Yeh, W.-S., Maroni, B., Li, Q., Lee, Y.-C., & Collard, H. R. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70101-8 · Cited by 716
Herbert, D. R., Hölscher, C., Mohrs, M., Arendse, B., Schwegmann, A., Radwanska, M., Leeto, M., Kirsch, R., Hall, P., Mossmann, H., et al. (2004) · Immunity · doi:10.1016/s1074-7613(04)00107-4 · Cited by 715
Hesse, M., Modolell, M., La Flamme, A. C., Schito, M., Fuentes, J. M., Cheever, A. W., Pearce, E. J., & Wynn, T. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6533 · Cited by 706
The Impact of TGF-β on Lung Fibrosis: From Targeting to Biomarkers
Fernandez, I. E., & Eickelberg, O. (2012) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201203-023aw · Cited by 679
Zuo, F., Kaminski, N., Eugui, E., Allard, J., Yakhini, Z., Ben-Dor, A., Lollini, L., Morris, D., Kim, Y., DeLustro, B., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092134099 · Cited by 620
Noth, I., Zhang, Y., Ma, S.-F., Flores, C., Barber, M., Huang, Y., Broderick, S. M., Wade, M. S., Hysi, P., Scuirba, J., et al. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70045-6 · Cited by 614
The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis
Molyneaux, P. L., Cox, M. J., Willis-Owen, S. A. G., Mallia, P., Russell, K. E., Russell, A.-M., Murphy, E., Johnston, S. L., Schwartz, D. A., Wells, A. U., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201403-0541oc · Cited by 567
Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature
Nalysnyk, L., Cid-Ruzafa, J., Rotella, P., & Esser, D. (2012) · European Respiratory Review · doi:10.1183/09059180.00002512 · Cited by 552
King, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531 · cited 1×
“Unfortunately, clinical trials that administered recombinant IFN-γ or an anti–IL-13 monoclonal antibody failed to show any clinical benefit in IPF patients (89, 90).”
MethodAnthony, R. M., Urban, J. F., Alem, F., Hamed, H. A., Rozo, C. T., Boucher, J.-L., Van Rooijen, N., & Gause, W. C. (2006) · Nature Medicine · doi:10.1038/nm1451 · Cited by 522
Khalil, N., O'Connor, R. N., Unruh, H. W., Warren, P. W., Flanders, K. C., Kemp, A., Bereznay, O. H., & Greenberg, A. H. (1991) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb/5.2.155 · Cited by 521
Khalil, N., Bereznay, O., Sporn, M., & Greenberg, A. H. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.3.727 · Cited by 505
A Vicious Circle of Alveolar Macrophages and Fibroblasts Perpetuates Pulmonary Fibrosis via CCL18
Prasse, A., Pechkovsky, D. V., Toews, G. B., Jungraithmayr, W., Kollert, F., Goldmann, T., Vollmer, E., Müller-Quernheim, J., & Zissel, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200509-1518oc · Cited by 497
Most Tissue-Resident Macrophages Except Microglia Are Derived from Fetal Hematopoietic Stem Cells
Sheng, J., Ruedl, C., & Karjalainen, K. (2015) · Immunity · doi:10.1016/j.immuni.2015.07.016 · Cited by 489
Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis
Gibbons, M. A., MacKinnon, A. C., Ramachandran, P., Dhaliwal, K., Duffin, R., Phythian-Adams, A. T., van Rooijen, N., Haslett, C., Howie, S. E., Simpson, A. J., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201010-1719oc · Cited by 466
Denton (2007) · doi:10.1002/art.22289 · Cited by 447
Animal Models of Fibrotic Lung Disease
B. Moore, B., Lawson, W. E., Oury, T. D., Sisson, T. H., Raghavendran, K., & Hogaboam, C. M. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0094tr · Cited by 412
Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice
Zhao, J., Shi, W., Wang, Y.-L., Chen, H., Bringas, P., Datto, M. B., Frederick, J. P., Wang, X.-F., & Warburton, D. (2002) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00151.2001 · Cited by 411
Han, M. K., Zhou, Y., Murray, S., Tayob, N., Noth, I., Lama, V. N., Moore, B. B., White, E. S., Flaherty, K. R., Huffnagle, G. B., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70069-4 · Cited by 411
Alveolar Epithelial Type II Cells as Drivers of Lung Fibrosis in Idiopathic Pulmonary Fibrosis
Parimon, T., Yao, C., Stripp, B. R., Noble, P. W., & Chen, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072269 · Cited by 375
Protection from Pulmonary Fibrosis in the Absence of CCR2 Signaling
Moore, B. B., Paine, R., Christensen, P. J., Moore, T. A., Sitterding, S., Ngan, R., Wilke, C. A., Kuziel, W. A., & Toews, G. B. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.8.4368 · Cited by 371
Treatment of Idiopathic Pulmonary Fibrosis with Etanercept: An Exploratory, Placebo-controlled Trial
Raghu, G., Brown, K. K., Costabel, U., Cottin, V., du Bois, R. M., Lasky, J. A., Thomeer, M., Utz, J. P., Khandker, R. K., McDermott, L., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200709-1446oc · Cited by 370
Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis
O’Dwyer, D. N., Ashley, S. L., Gurczynski, S. J., Xia, M., Wilke, C., Falkowski, N. R., Norman, K. C., Arnold, K. B., Huffnagle, G. B., Salisbury, M. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201809-1650oc · Cited by 366
Celada, L. J., Kropski, J. A., Herazo-Maya, J. D., Luo, W., Creecy, A., Abad, A. T., Chioma, O. S., Lee, G., Hassell, N. E., Shaginurova, G. I., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar8356 · Cited by 363
Yu, Y.-R. A., O’Koren, E. G., Hotten, D. F., Kan, M. J., Kopin, D., Nelson, E. R., Que, L., & Gunn, M. D. (2016) · PLOS ONE · doi:10.1371/journal.pone.0150606 · Cited by 361
Rice, L. M., Padilla, C. M., McLaughlin, S. R., Mathes, A., Ziemek, J., Goummih, S., Nakerakanti, S., York, M., Farina, G., Whitfield, M. L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77958 · Cited by 351
Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18–64 years old
Raghu, G., Chen, S.-Y., Hou, Q., Yeh, W.-S., & Collard, H. R. (2016) · European Respiratory Journal · doi:10.1183/13993003.01653-2015 · Cited by 338
Herazo-Maya, J. D., Noth, I., Duncan, S. R., Kim, S., Ma, S.-F., Tseng, G. C., Feingold, E., Juan-Guardela, B. M., Richards, T. J., Lussier, Y., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005964 · Cited by 325
Epidemiology of idiopathic pulmonary fibrosis
Ley, B., & Collard, H. (2013) · Clinical Epidemiology · doi:10.2147/clep.s54815 · Cited by 321
Baseline BAL Neutrophilia Predicts Early Mortality in Idiopathic Pulmonary Fibrosis
Kinder, B. W., Brown, K. K., Schwarz, M. I., Ix, J. H., Kervitsky, A., & King, T. E. (2008) · Chest · doi:10.1378/chest.07-1948 · Cited by 302
Coker, R. K., Laurent, G. J., Shahzeidi, S., Lympany, P. A., du Bois, R. M., Jeffery, P. K., & McAnulty, R. J. (1997) · Europe PMC (PubMed Central) · Cited by 292
Liang, J., Zhang, Y., Xie, T., Liu, N., Chen, H., Geng, Y., Kurkciyan, A., Mena, J. M., Stripp, B. R., Jiang, D., et al. (2016) · Nature Medicine · doi:10.1038/nm.4192 · Cited by 287 · cited 1×
“Senescence in type 2 alveolar epithelial cells also limits their self-renewal capacity and their ability to contribute to lung repair in the setting of epithelial injury (16, 17).”
BackgroundPivotal Advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation
Shao, D. D., Suresh, R., Vakil, V., Gomer, R. H., & Pilling, D. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.1107782 · Cited by 272
Neutrophils contribute to spontaneous resolution of liver inflammation and fibrosis via microRNA-223
Calvente, C. J., Tameda, M., Johnson, C. D., del Pilar, H., Lin, Y. C., Adronikou, N., De Mollerat Du Jeu, X., Llorente, C., Boyer, J., & Feldstein, A. E. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122258 · Cited by 268 · cited 1×
“In other models of tissue injury, neutrophils have even been shown to protect against fibrosis (74).”
BackgroundCarré, P. C., Mortenson, R. L., King, T. E., Noble, P. W., Sable, C. L., & Riches, D. W. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115501 · Cited by 253
Sandler, N. G., Mentink-Kane, M. M., Cheever, A. W., & Wynn, T. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.7.3655 · Cited by 251
Yang, D., Chen, X., Wang, J., Lou, Q., Lou, Y., Li, L., Wang, H., Chen, J., Wu, M., Song, X., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.02.001 · Cited by 250
Kodelja, V., Müller, C., Politz, O., Hakij, N., Orfanos, C. E., & Goerdt, S. (1998) · PubMed · Cited by 249
Matrix Metalloproteinase 3 Is a Mediator of Pulmonary Fibrosis
Yamashita, C. M., Dolgonos, L., Zemans, R. L., Young, S. K., Robertson, J., Briones, N., Suzuki, T., Campbell, M. N., Gauldie, J., Radisky, D. C., et al. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.06.041 · Cited by 247
Interaction of IL-13 and C10 in the Pathogenesis of Bleomycin-Induced Pulmonary Fibrosis
Belperio, J. A., Dy, M., Burdick, M. D., Xue, Y. Y., Li, K., Elias, J. A., & Keane, M. P. (2002) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2002-0009oc · Cited by 232
Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis
Kotsianidis, I., Nakou, E., Bouchliou, I., Tzouvelekis, A., Spanoudakis, E., Steiropoulos, P., Sotiriou, I., Aidinis, V., Margaritis, D., Tsatalas, C., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200812-1936oc · Cited by 230
Kodelja, V., Müller, C., Politz, O., Hakij, N., Orfanos, C. E., & Goerdt, S. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.3.1411 · Cited by 223
Neutrophil elastase promotes myofibroblast differentiation in lung fibrosis
Gregory, A. D., Kliment, C. R., Metz, H. E., Kim, K.-H., Kargl, J., Agostini, B. A., Crum, L. T., Oczypok, E. A., Oury, T. A., & Houghton, A. M. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3hi1014-493r · Cited by 216
Zhou, Y., Peng, H., Sun, H., Peng, X., Tang, C., Gan, Y., Chen, X., Mathur, A., Hu, B., Slade, M. D., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007096 · Cited by 215
Macrophage Activation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Schupp, J. C., Binder, H., Jäger, B., Cillis, G., Zissel, G., Müller-Quernheim, J., & Prasse, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116775 · Cited by 204
STEWART, J. P., EGAN, J. J., ROSS, A. J., KELLY, B. G., LOK, S. S., HASLETON, P. S., & WOODCOCK, A. A. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.4.9807077 · Cited by 204
Hou, J., Shi, J., Chen, L., Lv, Z., Chen, X., Cao, H., Xiang, Z., & Han, X. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0300-8 · Cited by 202
Zhang, J., Wang, D., Wang, L., Wang, S., Roden, A. C., Zhao, H., Li, X., Prakash, Y. S., Matteson, E. L., Tschumperlin, D. J., et al. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00301.2018 · Cited by 194
WHYTE, M., HUBBARD, R., MELICONI, R., WHIDBORNE, M., EATON, V., BINGLE, C., TIMMS, J., DUFF, G., FACCHINI, A., PACILLI, A., et al. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.2.9909053 · Cited by 189
The Toll-like Receptor 3 L412F Polymorphism and Disease Progression in Idiopathic Pulmonary Fibrosis
O’Dwyer, D. N., Armstrong, M. E., Trujillo, G., Cooke, G., Keane, M. P., Fallon, P. G., Simpson, A. J., Millar, A. B., McGrath, E. E., Whyte, M. K., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201304-0760oc · Cited by 186
Expression of TNF and the Necessity of TNF Receptors in Bleomycin-Induced Lung Injury in Mice
Ortiz, L. A., Lasky, J., Hamilton, R. F., Holian, A., Hoyle, G. W., Banks, W., Peschon, J. J., Brody, A. R., Lungarella, G., & Friedman, M. (1998) · Experimental Lung Research · doi:10.3109/01902149809099592 · Cited by 181
Kapançi, Y., Desmoulière, A., Pache, J. C., Redard, M., & Gabbiani, G. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.152.6.8520791 · Cited by 174
Desch, A. N., Gibbings, S. L., Goyal, R., Kolde, R., Bednarek, J., Bruno, T., Slansky, J. E., Jacobelli, J., Mason, R., Ito, Y., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201507-1376oc · Cited by 171
Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro
Saito, A., Okazaki, H., Sugawara, I., Yamamoto, K., & Takizawa, H. (2003) · International Archives of Allergy and Immunology · doi:10.1159/000073718 · Cited by 167
Plasma B Lymphocyte Stimulator and B Cell Differentiation in Idiopathic Pulmonary Fibrosis Patients
Xue, J., Kass, D. J., Bon, J., Vuga, L., Tan, J., Csizmadia, E., Otterbein, L., Soejima, M., Levesque, M. C., Gibson, K. F., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203476 · Cited by 161
Mitsi, E., Kamng’ona, R., Rylance, J., Solórzano, C., Reiné, J., Mwandumba, H. C., Ferreira, D. M., & Jambo, K. (2018) · Respiratory Research · doi:10.1186/s12931-018-0777-0 · Cited by 148
Betensley, A. D., Sharif, R., & Karamichos, D. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm6010002 · Cited by 140
PD-1 hi CD8 + resident memory T cells balance immunity and fibrotic sequelae
Wang, Z., Wang, S., Goplen, N. P., Li, C., Cheon, I. S., Dai, Q., Huang, S., Shan, J., Ma, C., Ye, Z., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aaw1217 · Cited by 139
Fra-2–expressing macrophages promote lung fibrosis
Ucero, A. C., Bakiri, L., Roediger, B., Suzuki, M., Jiménez, M., Mandal, P., Braghetta, P., Bonaldo, P., Paz-Ares, L. G., Torre, C. F., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125366 · Cited by 131
Hallowell, R. W., Collins, S. L., Craig, J. M., Zhang, Y., Oh, M., Illei, P. B., Chan-Li, Y., Vigeland, C. L., Mitzner, W., Scott, A. L., et al. (2017) · Nature Communications · doi:10.1038/ncomms14208 · Cited by 129
Self-citationA phase 2 randomized controlled study of tralokinumab in subjects with idiopathic pulmonary fibrosis
Parker, J. M., Glaspole, I. N., Lancaster, L. H., Haddad, T. J., She, D., Roseti, S. L., Fiening, J. P., Grant, E. P., Kell, C. M., & Flaherty, K. R. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201704-0784oc · Cited by 129
Nuovo, G. J., Hagood, J. S., Magro, C. M., Chin, N., Kapil, R., Davis, L., Marsh, C. B., & Folcik, V. A. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.166 · Cited by 123
Allden, S., Ogger, P. P., Ghai, P., McErlean, P. K., Hewitt, R., Toshner, R., Walker, S. A., Saunders, P. T., Kingston, S., Molyneaux, P. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201809-1775oc · Cited by 118
Exacerbation of Established Pulmonary Fibrosis in a Murine Model by Gammaherpesvirus
McMillan, T. R., Moore, B. B., Weinberg, J. B., Vannella, K. M., Fields, W. B., Christensen, P. J., van Dyk, L. F., & Toews, G. B. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200708-1184oc · Cited by 113
Thrall, R. S., Phan, S. H., McCormick, J. R., & Ward, P. A. (1981) · PubMed · Cited by 111
Resistance to Bleomycin-Induced Lung Fibrosis in MMP-8 Deficient Mice Is Mediated by Interleukin-10
García-Prieto, E., González-López, A., Cabrera, S., Astudillo, A., Gutiérrez‐Fernández, A., Fanjul‐Fernández, M., Batalla-Solís, E., Puente, X. S., Fueyo, A., López-Otı́n, C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013242 · Cited by 108
Hoffmann, K. F., McCarty, T. C., Segal, D., Chiaramonte, M. G., Hesse, M., Davis, E. M., Cheever, A. W., Meltzer, P. S., Morse, H. C., & Wynn, T. A. (2001) · The FASEB Journal · doi:10.1096/fj.01-0306fje · Cited by 104
Inflammatory Cell Phenotyping of the Pulmonary Interstitium in Idiopathic Interstitial Pneumonia
Parra, E. R., Kairalla, R. A., de Carvalho, C. R. R., Eher, E. M., & Capelozzi, V. L. (2006) · Respiration · doi:10.1159/000097133 · Cited by 96
Galati, D., De Martino, M., Trotta, A., Rea, G., Bruzzese, D., Cicchitto, G., Stanziola, A. A., Napolitano, M., Sanduzzi, A., & Bocchino, M. (2014) · Cytokine · doi:10.1016/j.cyto.2013.12.003 · Cited by 95
Telomerase and Telomere Length in Pulmonary Fibrosis
Liu, T., Ullenbruch, M. R., Choi, Y. Y., Yu, H., Ding, L., Xaubet, A., Pereda, J., Feghali‐Bostwick, C. A., Bitterman, P. B., Henke, C. A., et al. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0514oc · Cited by 93
CD4+CD25hiFoxp3+ Cells Exacerbate Bleomycin-Induced Pulmonary Fibrosis
Birjandi, S. Z., Palchevskiy, V., Xue, Y., Nuñez, S., Kern, R. M., Weigt, S. S., Lynch, J. P., Chatila, T. A., & Belperio, J. A. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.03.020 · Cited by 89
IL‐17A deficiency mitigates bleomycin‐induced complement activation during lung fibrosis
Cipolla, E., Fisher, A. J., Gu, H., Mickler, E. A., Agarwal, M., Wilke, C. A., Kim, K. K., Moore, B. B., & Vittal, R. (2017) · The FASEB Journal · doi:10.1096/fj.201700289r · Cited by 89
CD19 regulates the development of bleomycin‐induced pulmonary fibrosis in a mouse model
Komura, K., Yanaba, K., Horikawa, M., Ogawa, F., Fujimoto, M., Tedder, T. F., & Sato, S. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23995 · Cited by 86
Heukels, P., van Hulst, J. A. C., van Nimwegen, M., Boorsma, C. E., Melgert, B. N., von der Thüsen, J. H., van den Blink, B., Hoek, R. A. S., Miedema, J., Neys, S. F. H., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1195-7 · Cited by 80
IL-21 Promotes Pulmonary Fibrosis through the Induction of Profibrotic CD8+ T Cells
Brodeur, T. Y., Robidoux, T. E., Weinstein, J. S., Craft, J. E., Swain, S. L., & Marshak‐Rothstein, A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500777 · Cited by 79
IL1RN genetic variations and risk of IPF: a meta-analysis and mRNA expression study
Korthagen, N. M., van Moorsel, C. H. M., Kazemier, K. M., Ruven, H. J. T., & Grutters, J. C. (2012) · Immunogenetics · doi:10.1007/s00251-012-0604-6 · Cited by 78
CD8+ T lymphocytes in lung tissue from patients with idiopathic pulmonary fibrosis
Daniil, Z. D., Kitsanta, P., Kapotsis, G. E., Mathioudaki, M., Kollintza, A., Karatza, M., Milic‐Emili, J., Roussos, C., & Papiris, S. A. (2005) · Respiratory Research · doi:10.1186/1465-9921-6-81 · Cited by 73
Hou, Z., Ye, Q., Qiu, M., Yu, H., Han, J., & Zeng, H. (2017) · Respiratory Research · doi:10.1186/s12931-017-0653-3 · Cited by 73
Xiong, S., Guo, R., Yang, Z., Xu, L., Du, L., Li, R., Xiao, F., Wang, Q., Zhu, M., & Pan, X. (2015) · Immunobiology · doi:10.1016/j.imbio.2015.07.001 · Cited by 69
Boomars, K. A., Wagenaar, S. S., Mulder, P. G. H., van Velzen‐Blad, H., & van den Bosch, J. M. (1995) · Thorax · doi:10.1136/thx.50.10.1087 · Cited by 67
Pulmonary CCR2+CD4+T cells are immune regulatory and attenuate lung fibrosis development
Milger, K., Yu, Y., Brudy, E., Irmler, M., Skapenko, A., Mayinger, M. C., Lehmann, M., Beckers, J., Reichenberger, F., Behr, J., et al. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-208423 · Cited by 65
Characterization of CD28null T cells in idiopathic pulmonary fibrosis
Habiel, D. M., Espíndola, M. S., Kitson, C., Azzara, A. V., Coelho, A. L., Stripp, B. R., & Hogaboam, C. M. (2018) · Mucosal Immunology · doi:10.1038/s41385-018-0082-8 · Cited by 64
The Th1/Th17 balance dictates the fibrosis response in murine radiation-induced lung disease
Paun, A., Bergeron, M.-E., & Haston, C. K. (2017) · Scientific Reports · doi:10.1038/s41598-017-11656-5 · Cited by 59
Papiris, S. A., Kollintza, A., Kitsanta, P., Kapotsis, G. E., Karatza, M., Milic-Emili, J., Roussos, C., & Daniil, Z. D. (2005) · CHEST Journal · doi:10.1016/s0012-3692(15)52722-0 · Cited by 58
Bleomycin-induced pulmonary fibrosis is independent of eosinophils
Hao, H., Cohen, D. A., JENNINGS, C. D., Bryson, J. S., & Kaplan, A. M. (2000) · Journal of Leukocyte Biology · doi:10.1189/jlb.68.4.515 · Cited by 57
Emura, M., NAGAI, S., Takeuchi, M., Kitaichi, M., & Izumi, T. (1990) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1990.tb05416.x · Cited by 51
Influence of early neutrophil depletion on MMPs/TIMP-1 balance in bleomycin-induced lung fibrosis
Manoury, B., Nénan, S., Guénon, I., Lagente, V., & Boichot, E. (2007) · International Immunopharmacology · doi:10.1016/j.intimp.2007.02.009 · Cited by 50
Epithelial fibroblast triggering and interactions in pulmonary fibrosis
Noble, P. W. (2008) · European Respiratory Review · doi:10.1183/09059180.00010904 · Cited by 43
Impact of Treg on other T cell subsets in progression of fibrosis in experimental lung fibrosis
Chakraborty, K., Chatterjee, S., & Bhattacharyya, A. (2018) · Tissue and Cell · doi:10.1016/j.tice.2018.06.003 · Cited by 38
Rac2 is involved in bleomycin-induced lung inflammation leading to pulmonary fibrosis
Arizmendi, N. G., Puttagunta, L., Chung, K. L., Davidson, C. E., Rey-Perra, J., Chao, D. V., Thébaud, B., Lacy, P., & Vliagoftis, H. (2014) · Respiratory Research · doi:10.1186/1465-9921-15-71 · Cited by 37
Joshi, S., Singh, A. R., Wong, S. S., Zulcic, M., Jiang, M., Pardo, A., Selman, M., Hagood, J. S., & Durden, D. L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182851 · Cited by 37
Braun, R. K., Foerster, M., Grahmann, P. R., Haefner, D., Workalemahu, G., & Kroegel, C. (2003) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.10021 · Cited by 33
Pulmonary Vaccination as a Novel Treatment for Lung Fibrosis
Collins, S. L., Chan‐Li, Y., Hallowell, R. W., Powell, J. D., & Horton, M. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031299 · Cited by 28
Self-citationVaccinia vaccine–based immunotherapy arrests and reverses established pulmonary fibrosis
Collins, S. L., Chan‐Li, Y., Oh, M. H., Vigeland, C. L., Limjunyawong, N., Mitzner, W., Powell, J. D., & Horton, M. R. (2016) · JCI Insight · doi:10.1172/jci.insight.83116 · Cited by 28
Self-citationLiu, Y., Saito, S., Morris, G. F., Miller, C. A., Li, J., & Lefante, J. J. (2018) · Genomics · doi:10.1016/j.ygeno.2018.09.006 · Cited by 22
Akella, P., Loganathan, S., Jindal, V., Akhtar, J., & Lal, A. (2018) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2018.11.005 · Cited by 22
Intrapulmonary Autoantibodies to HSP72 Are Associated with Improved Outcomes in IPF
Mills, R., Mathur, A., Nicol, L. M., Walker, J. J., Przybylski, A. A., MacKinnon, A. C., Howie, S., Wallace, W. A., Dransfield, I., & Hirani, N. (2019) · Journal of Immunology Research · doi:10.1155/2019/1845128 · Cited by 20
Cited by
Kou, M., Huang, L., Yang, J., Chiang, Z., Chen, S., Liu, J., Guo, L., Zhang, X., Zhou, X., Xu, X., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05034-x · Cited by 640
Mesenchymal stem cells in fibrotic diseases—the two sides of the same coin
Qin, L., Liu, N., Bao, C.-L.-M., Yang, D.-Z., Ma, G.-X., Yi, W.-H., Xiao, G.-Z., & Cao, H.-L. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00952-0 · Cited by 114
“Evidence showed that the microenvironment of fibrotic tissues is detected with a high level of ROS [249], increasing alternations and stiffness of ECMs [250], accompanied with a pre-inflammatory environment featured with increasing NK cells and regulatory T cells [251, 252].”
BackgroundImmune cell dysregulation as a mediator of fibrosis in systemic sclerosis
Fang, D., Chen, B., Lescoat, A., Khanna, D., & Mu, R. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00864-7 · Cited by 84
Stem cell-based therapy for pulmonary fibrosis
Cheng, W., Zeng, Y., & Wang, D. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03181-8 · Cited by 65
Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies
Selvarajah, B., Platé, M., & Chambers, R. C. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101227 · Cited by 57
Metadata
- Authors
- Shenderov, K., Collins, S. L., Powell, J. D., & Horton, M. R.
- Venue
- Journal of Clinical Investigation
- Published
- 2021-01-19
- Volume
- 131
- Issue
- 2
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3125375207
- Cited by
- 295
- References
- 124
- FWCI
- 25.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.